戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 itive to the topoisomerase II-targeting drug amsacrine.
2 agents, including etoposide, adriamycin, and amsacrine.
3 ntitatively unique pattern of sensitivity to amsacrine.
4 II isoforms, alpha and beta, are targeted by amsacrine.
5 ant to the cytotoxic effects of etoposide or amsacrine.
6 randomized study compared the combination of amsacrine (100 mg/m2/d on days 1 to 5) and etoposide (20
7 plus cytarabine (12 g/m(2)) and one cycle of amsacrine (500 mg/m(2)) plus cytarabine (10 g/m(2); MAC/
8 itive top2 mutants resistant to etoposide or amsacrine also confer resistance to DMP-840.
9 atients given ara-C with either doxorubicin, amsacrine (AMSA), or daunorubicin without ATRA, using lo
10 toposide, and azatoxin and the intercalators amsacrine and mitoxantrone.
11 lamino)-3-methoxyphenyl]methane-sulfonamide (amsacrine) and single-stranded DNA showed that the two a
12 g topo II inhibitors, etoposide, teniposide, amsacrine, and doxorubicin, but not to other catalytic i
13 somerase II inhibitors, such as etoposide, m-amsacrine, and doxorubicin.
14 otherapeutic drugs (etoposide, mitoxantrone, amsacrine, and ellipticine).
15 ge sites in the presence of VP-16, azatoxin, amsacrine, and mitoxantrone.
16 signed to GO in course 3 in combination with amsacrine, cytarabine, and etoposide or high-dose cytara
17  and idarubicin (FLAG-Ida; n = 1268), and to amsacrine, cytarabine, etoposide, and then mitoxantrone/
18 hat is, idarubicine-cytarabine (cycle I) and amsacrine-cytarabine (cycle II) without or with clofarab
19 the addition of azacitidine to etoposide and amsacrine did not improve response.
20                      The intercalative drugs amsacrine, ellipticine, and daunorubicin inhibited NaeI-
21 conferred cellular resistance to CP-115,953, amsacrine, etoposide, and ellipticine.
22 rial quinolone) on the ability of etoposide, amsacrine, genistein, and the antineoplastic quinolone,
23 ateau-phase cells, aprt mutations induced by amsacrine in both log-phase and plateau-phase CHO cells
24 tiagent consolidation using mitoxantrone and amsacrine in combination with high-dose cytarabine does
25  7 x 10(-6) after treatment with 0.02 microM amsacrine in log phase and 27 x 10(-6) after treatment w
26 nd 27 x 10(-6) after treatment with 1 microM amsacrine in plateau phase, compared with a spontaneous
27 es in DNA treated with topoisomerase II plus amsacrine in vitro.
28 , presence of trisomy 21, and treatment with amsacrine increase the risk for anthracycline-associated
29 itivity of HL-60/S or HL-60/DOX0.05 cells to amsacrine may be due to the preferential interaction and
30 ce of trisomy 21 (RR = 3.4), and exposure to amsacrine (RR = 2.6).
31 n both parental sequences were hot spots for amsacrine-stimulated DNA cleavage in vitro, and the nove
32 more, anticancer drugs such as etoposide and amsacrine that strongly inhibit topoisomerase II-mediate
33 ry D422 cells by the topoisomerase II poison amsacrine, there was a reciprocal exchange between the a
34 th drug for 1 h revealed that mole-for-mole, amsacrine was 2-fold more effective than etoposide in ki

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。